Join

Compare · BEN vs HQL

BEN vs HQL

Side-by-side comparison of Franklin Resources Inc. (BEN) and abrdn Life Sciences Investors Shares of Beneficial Interest (HQL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BEN and HQL operate in Investment Managers (Finance), so they compete in similar markets.
  • BEN is the larger of the two at $16.31B, about 38.1x HQL ($428.1M).
  • BEN has been more active in the news (10 items in the past 4 weeks vs 2 for HQL).
  • BEN has more recent analyst coverage (24 ratings vs 0 for HQL).
MetricBENHQL
Company
Franklin Resources Inc.
abrdn Life Sciences Investors Shares of Beneficial Interest
Price
-
-
Market cap
$16.31B
$428.1M
1M return
-
-
1Y return
-
-
Industry
Investment Managers
Investment Managers
Exchange
NYSE
NYSE
IPO
1992
News (4w)
10
2
Recent ratings
24
0
BEN

Franklin Resources Inc.

Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.

HQL

abrdn Life Sciences Investors Shares of Beneficial Interest

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Latest BEN

Latest HQL